NEUMORA THERAPEUTICS, INC. COMMON STOCK

NASDAQ: NMRA (Neumora Therapeutics, Inc.)

Last update: yesterday, 6:25AM

13.02

0.31 (2.44%)

Previous Close 12.71
Open 12.86
Volume 1,061,985
Avg. Volume (3M) 922,364
Market Cap 2,083,564,672
Price / Book 4.92
52 Weeks Range
8.33 (-36%) — 21.00 (61%)
Diluted EPS (TTM) -1.72
Total Debt/Equity (MRQ) 0.95%
Current Ratio (MRQ) 17.23
Operating Cash Flow (TTM) -198.33 M
Levered Free Cash Flow (TTM) -133.95 M
Return on Assets (TTM) -37.75%
Return on Equity (TTM) -77.08%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Neumora Therapeutics, Inc. Mixed Bullish

Stockmoo Score

0.9
Analyst Consensus 5.0
Insider Activity NA
Price Volatility -1.0
Technical Moving Averages 0.0
Technical Oscillators -0.5
Average 0.88

Similar Stocks

Stock Market Cap DY P/E P/B
NMRA 2 B - - 4.92
BNTX 27 B - - 1.43
CNTA 2 B - - 6.76
UPB 1 B - - -
ELVN 1 B - - 4.28
BCAX 1 B - - -

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 28.00%
% Held by Institutions 61.78%

Ownership

Name Date Shares Held
Mic Capital Management Uk Llp 30 Jun 2024 4,460,700
Iconiq Capital, Llc 30 Jun 2024 3,398,628
Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust 30 Sep 2024 3,309,123
Artal Group S.A. 30 Jun 2024 2,824,052
Johnson & Johnson 30 Jun 2024 1,849,445
Avidity Partners Management Lp 30 Jun 2024 1,800,000
52 Weeks Range
8.33 (-36%) — 21.00 (61%)
Price Target Range
15.00 (15%) — 30.00 (130%)
High 30.00 (HC Wainwright & Co., 130.42%) Buy
Median 26.00 (99.69%)
Low 15.00 (JP Morgan, 15.21%) Hold
Average 24.25 (86.25%)
Total 3 Buy, 1 Hold
Avg. Price @ Call 13.22
Firm Date Target Price Call Price @ Call
JP Morgan 05 Nov 2024 15.00 (15.21%) Hold 11.91
Needham 18 Oct 2024 23.00 (76.65%) Buy 16.49
12 Sep 2024 23.00 (76.65%) Buy 11.83
HC Wainwright & Co. 01 Oct 2024 30.00 (130.41%) Buy 13.50
RBC Capital 04 Sep 2024 29.00 (122.73%) Buy 10.99

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria